TABLE 1

Characteristics of study populations

C by groupEffectiveSex ratio female/maleAge yearsAge at time of diagnosis yearsPAH form
IdiopathicDrug or toxin-inducedHeritable with BMPR2 mutationHeritable without BMPR2 mutationPVOD
PAH
 Total992.256.2 (20.2–84.6)50.6 (16.3–81.9)50 (50.5)15 (15.2)16 (16.2)5 (5.0)13 (13.1)
 C=029 (29.3)1.466.0 (24.6–80.8)58.7 (16.3–79.1)12 (41.4)6 (20.7)4 (13.8)07 (24.1)
 C=18 (8.1)0.671.0 (20.2–84.6)59.4 (16.3–81.9)5 (62.5)1 (12.5)1 (12.5)01 (12.5)
 C=2–1039 (39.4)2.953.4 (20.9–75.3)41.1 (19.9–73.9)18 (46.2)6 (17.9)8 (20.5)3 (3.7)4 (7.7)
 C>1023 (23.2)4.842.1 (21.7–71.0)38.2 (21.6–69.4)15 (65.2)2 (8.7)3 (13.1)2 (8.7)1 (4.3)
Controls
 Total58152.3 (27.3–82.8)
 C=012 (20.7)165.3 (31.4–82.8)
 C=16 (10.3)553.9 (30.6–73.5)
 C=2–1026 (44.8)0.549.3 (27.3–77.3)
 C>1014 (24.1)1.850.2 (30.0–68.0)
  • Data are presented as n, n (%) or median (range). BMPR2: bone morphogenetic protein receptor type II; PVOD: pulmonary veno-occlusive disease.